Arvinas (ARVN) Profit After Tax (2017 - 2026)
Arvinas (ARVN) recorded quarterly Profit After Tax of -$57.6 million in Q1 2026, up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025, and down 169.48% on a YoY basis from $82.9 million in Q1 2025.
Arvinas (ARVN) Profit After Tax (2017 - 2026) Analysis & Trends
Arvinas' Profit After Tax history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 169.48% year-over-year to -$57.6 million; the TTM figure through Mar 2026 stood at -$221.3 million (down 374.89% YoY), while the FY2025 annual figure was -$80.8 million, up 59.38% from the prior year.
- Profit After Tax was -$57.6 million for Q1 2026 at Arvinas, up from -$67.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $82.9 million in Q1 2025 to a low of -$154.8 million in Q4 2023.
- Historically, Profit After Tax has averaged -$58.1 million across 5 years, with a median of -$64.0 million in 2023.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax soared 219.45% in 2025, then sank 169.48% in 2026.
- A 5-year view of Profit After Tax shows it stood at -$82.9 million in 2022, then sank by 86.73% to -$154.8 million in 2023, then jumped by 70.87% to -$45.1 million in 2024, then slumped by 49.45% to -$67.4 million in 2025, then advanced by 14.54% to -$57.6 million in 2026.
- The last three Profit After Tax figures came in at -$57.6 million (Q1 2026), -$67.4 million (Q4 2025), and -$35.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | -57.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -64.00 Mn |
| Jun 30, 2023 | -66.60 Mn |
| Mar 31, 2023 | -81.90 Mn |
| Dec 31, 2022 | -82.90 Mn |
| Sep 30, 2022 | -66.20 Mn |
| Jun 30, 2022 | -70.00 Mn |
| Mar 31, 2022 | -63.40 Mn |
| Dec 31, 2021 | -53.00 Mn |
| Sep 30, 2021 | -46.80 Mn |
| Jun 30, 2021 | -50.30 Mn |